New York City-based money manager North Street Global announced that hedge fund industry veteran Kira Bazile has joined as president. Bazile, with over 17-years experience in the prime brokerage component of the hedge fund industry, will head business development for the firm’s fund administration platform, capital introductions group and global markets division. Most recently, she was a managing director at BTIG where she focused on developing its prime brokerage product for emerging managers.
Prior to that, she then worked at Deutsche Bank for eight years where she helped build the financing and derivatives platform within the newly formed global prime services division. She began her prime brokerage career at Goldman Sachs in 1997 where she spent four years managing a client service team.
Market consultancy TABB Group promoted Paul Rowady to principal, and also named him head of research for new data & analytics (DnA) IT practice. Rowady, a pro with over 24 years of proprietary trading and capital markets experience, has a background in strategy research, risk management and trading technology, with specific expertise in derivatives, highly automated trading systems and data management initiatives.
Rowady joined TABB Group as a senior research analyst in 2009 from Alphacution LLC, which he founded, focusing on design and development for market intelligence and data management systems and where he holds a patent for an automated event-risk research platform. From 2001 to 2004, he was managing director of research at Ritchie Capital Management, a multi-strategy hedge fund manager where, in addition to leading the research team and business development for major investors, he designed a centralized trading intelligence system and directed development of a customized investor relationship management system, instrumental in achieving AuM of $3 billion. From 1996 to 2004, he was a partner and chief investment officer at Quantlab Financial, LLC, leading the development of highly-automated trading strategies. He began his career as a research analyst and portfolio manager at O’Connor & Associates, LP.
Exchange operator NasdaqOMX appointed Thomas Wittman as executive vice president, and global head of equities. Wittman will oversee the global cash equities and equity derivatives businesses. Prior to this, he was senior vice president, head of U.S. equities and derivatives and president of NASDAQ OMX PHLX.
Wittman was responsible for the management and operations of NasdaqOMX’s three U.S. equities markets, three U.S. options markets, and the futures market. Formerly vice president of U.S. Options, he led the team in transitioning the NasdaOMX PHLX platform from an open outcry, floor-based specialist system to an electronic, hybrid system. He also drove the development of the NASDAQ Options Market (NOM) and the launch of NasdaqOMX BX Options (BX Options). He came to Nasdaq via its acquisition of PHLX, formerly The Philadelphia Stock Exchange, in 2008. At PHLX, he supported the electronic equity trading business, equity options business, PBOT futures business and the supporting surveillance and back office systems. He reports to Hans-Ole Jochumsen, president, global trading & market services, a position he recently acquired.
WallachBeth has added Brian Jeep as lead pharmaceutical analyst in the firm’s health-care research group. Jeep, a six-year pro, comes from Wells Fargo Securities where he was a vice president in its pharmaceuticals equity research group. Previously, he was with Sidoti & Company, where he served as lead analyst/health-care research and focused on small-cap stocks within the Pharmaceuticals, Drug Delivery and Diagnostics sectors. Prior to his Wall Street career, Jeep was with GlaxoSmithKline from 2001 to 2008. He reports to Doug Bantum, Managing Director, Healthcare Research Sales/Trading.
